share_log

bluebird bio | DEFA14A: Others

bluebird bio | DEFA14A: Others

bluebird bio | DEFA14A：其他
美股SEC公告 ·  2024/10/15 20:04

Moomoo AI 已提取核心訊息

bluebird bio, Inc. has filed supplemental disclosure with the SEC, amending its definitive proxy statement ahead of the annual meeting of stockholders scheduled for November 6, 2024. The company clarified who would bear the costs of soliciting proxies, stating that it would cover these expenses, primarily through mail and Internet, with additional outreach by employees and third-party firm Innisfree M&A Incorporated, for a fee not exceeding $30,000 plus expenses. Furthermore, bluebird bio addressed its non-compliance with Nasdaq's Minimum Bid Price Requirement, revealing that its stock closed below the $1.00 threshold for 32 consecutive business days. The company received a notice from Nasdaq on September 30, 2024, and has until March 31, 2025, to meet the requirement or face potential delisting. The company may seek an additional compliance period by transferring to the Nasdaq Capital Market, but there is no assurance of regaining compliance or maintaining other listing requirements.
bluebird bio, Inc. has filed supplemental disclosure with the SEC, amending its definitive proxy statement ahead of the annual meeting of stockholders scheduled for November 6, 2024. The company clarified who would bear the costs of soliciting proxies, stating that it would cover these expenses, primarily through mail and Internet, with additional outreach by employees and third-party firm Innisfree M&A Incorporated, for a fee not exceeding $30,000 plus expenses. Furthermore, bluebird bio addressed its non-compliance with Nasdaq's Minimum Bid Price Requirement, revealing that its stock closed below the $1.00 threshold for 32 consecutive business days. The company received a notice from Nasdaq on September 30, 2024, and has until March 31, 2025, to meet the requirement or face potential delisting. The company may seek an additional compliance period by transferring to the Nasdaq Capital Market, but there is no assurance of regaining compliance or maintaining other listing requirements.
bluebird bio公司已向SEC提交補充披露，修訂其在2024年11月6日股東年會前的最終代理聲明。公司澄清了誰將承擔代理律師費用，表示將通過郵件和互聯網主要覆蓋這些費用，員工和第三方公司Innisfree M&A Incorporated還將進行額外的宣傳，費用不超過30,000美元加雜費。此外，bluebird bio提到了其不符合納斯達克的最低報價要求，透露其股票連續32個交易日收盤低於1.00美元的閾值。公司在2024年9月30日收到了納斯達克的通知，需在2025年3月31日前滿足要求，否則將面臨潛在的除牌。公司可以通過轉至納斯達克資本市場尋求額外的合規期限，但無法保證重新符合要求或符合其他上市要求。
bluebird bio公司已向SEC提交補充披露，修訂其在2024年11月6日股東年會前的最終代理聲明。公司澄清了誰將承擔代理律師費用，表示將通過郵件和互聯網主要覆蓋這些費用，員工和第三方公司Innisfree M&A Incorporated還將進行額外的宣傳，費用不超過30,000美元加雜費。此外，bluebird bio提到了其不符合納斯達克的最低報價要求，透露其股票連續32個交易日收盤低於1.00美元的閾值。公司在2024年9月30日收到了納斯達克的通知，需在2025年3月31日前滿足要求，否則將面臨潛在的除牌。公司可以通過轉至納斯達克資本市場尋求額外的合規期限，但無法保證重新符合要求或符合其他上市要求。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    美聯儲暫停降息，你如何調整持倉？
    美聯儲宣布基準利率維持在4.25%—4.50%不變，符合市場預期。你會如何配置資產？ 展开
    FOMC新聞發佈會，2025年1月29日